Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin’s Lymphomas

05-Dec-2014 - Denmark

Genmab A/S announced that its collaboration partner, Janssen Biotech, Inc. (Janssen) plans to start a Phase II study of daratumumab in non-Hodgkin’s lymphomas (NHL).  The study (LYM2001) will evaluate daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL).  The study is expected to start enrolling patients in 2015.

“With this study we are expanding the scope of the daratumumab development program, beyond multiple myeloma, into NHL, another disease area where new treatment options are needed, and where daratumumab has shown anti-tumor activity in pre-clinical disease models,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances